Aerie Pharma (AERI) PT Lifted to $50 at Stifel on Strong Roclatan Results
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Stifel analyst Annabel Samimy reiterated a Buy rating and boosted his price target on Aerie Pharma (NASDAQ: AERI) to $50.00 (from $40.00) after the company reported unequivocally positive results from its Phase 3 Roclatan MERCURY-1 study. This 90-day primary efficacy readout demonstrated statistically significant IOP-lowering of Roclatan over its Rhopressa and latanoprost components at clinically-meaningful levels of 1-3mmHg at all nine time points with no significant safety deviations from prior studies. Specifically, Roclatan was superior to latanoprost by 1.3-2.5mmHg (p<0.0001) and to Rhopressa by 1.8-3.0mmHg (p<0.0001).
Samimy commented, "mportantly, in a responder analysis, 46% of Roclatan patients achieved >35% reductions in IOP (p<0.0001) and 61% achieving <16mmHg at Day 90—key targets for ophthalmologists. We believe this clean readout of data goes far to de-risk the Roclatan/MERCURY program and we have confidence for consistent readouts at 12-months and for MERCURY-2. AERI looks to a year-end 2017 NDA filing for Roclatan."
Shares of Aerie Pharma closed at $21.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on Kroger (KR) to $30 Following 3Q and Guidance
- Oppenheimer Cuts Price Target on Workday (WDAY) Following 3Q; Reiterates Outperform
- Jefferies Cuts Price Target on PG&E Corp. (PCG) to $65 Following Rate Case Decision
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!